9 results
Primary objective: To investigate the effectiveness of ongoing treatment with methylphenidate as prescribed in clinical practice beyond two years in children and adolescents. Secondary objectives:(1) to investigate the effects of discontinuation of…
The primary aim of our study will be to investigate the effectiveness of PCIT in comparison with methylphenidate in children with ADHD and disruptive behavior problems aged 2;6 till 6 years who have not responded sufficiently to previously offered…
Primary:The primary objective of this study is to evaluate the efficacy of LDX administered as a daily morning dose (30, 50, and 70mg/day) compared to placebo over the course of 7 weeks. This study will enrol children and adolescents (6-17 years of…
Primary objective of the study: 1. To report on the effectmodification by age of MPH treatment on the outgrowth of the DA system using state-of-the-art Magnetic Resonance Imaging (MRI) techniquesSecondary objectives:1. To report on the…
The purpose of this study is to evaluate the efficacy of two antibiotics ( neomycin sulfate and colistin sulfate), followed by fecal bacteria therapy , to multidrug - resistant bacteria (E - ESBL and EPC) to be eradicated from the intestine.
The comparison of the effects (and cost effectiveness) of mindfulness training for the child + Mindful Parenting for the parents versus medication (Methylphenidate) in a randomized controlled trial (RCT) in children with ADHD, aged 9-18.
Primary:- To test whether bevacizumab added to a backbone chemotherapy regimen (temozolomide or irinotecan-temozolomide or topotecan-temozolomide) demonstrates activity in children with relapsed or refractory neuroblastoma- To test whether the…
The primary goal of this study is to investigate whether placebo-controlled double-blind titration leads to optimizing the use of methylphenidate. This by detecting placebo-and non-responders more efficiently and by treating responders better so…
Investigate whether perioperative mFOLFIRINOX improves overall survival compared to adjuvant mFOLFIRINOX in resectable pancreatic cancer.